Risk Prediction and Prognosis of Invasive Fungal Disease in Hematological Malignancies Patients Complicated with Bloodstream Infections
Risk Prediction and Prognosis of Invasive Fungal Disease in Hematological Malignancies Patients Complicated with Bloodstream Infections
复制标题
血液系统恶性肿瘤并发血流感染患者侵袭性真菌病的风险预测和预后
DOI:
10.2147/cmar.s238166
复制
发表时间:
2020-03
影响因子:
3.3
通讯作者:
Li Xin
中科院分区:
文献类型:
--
作者:
Xiao Han;Tang Yishu;Cheng Qian;Liu Jing;Li Xin
Purpose: In patients with hematologic malignancies (HM), bloodstream infections (BSI) and invasive fungal disease (IFD) remain important complications causing considerable mortality and morbidity. At present, the morbidity of IFD and the strategies to initiate antifungal treatment in HM patients with BSI remain unclear. Patients and Methods: Patient characteristics, infection-related variables, and therapy-related features of 1374 HM patients with proven BSI from three hospitals were reviewed to investigate the epidemiology, risk factors and prognosis of IFD. Results: The morbidity of proven and probable IFD in HM patients with BSI was 11.2%, and the mortality of those patients was 40.5%. Existing IFD risk scores were not accurate enough in distinguishing these patients benefiting from antifungal prophylaxis. Multivariate logistic regression identified age >45 years, profound neutropenia, hypoproteinemia, and use of vasopressors as independent variables associated with IFD morbidity in HM patients with BSI. In patients with proven and probable IFD patients, age >45 years, Pitt bacteremia score >3, use of vasopressors, abnormal blood coagulation, and initiation of antifungal therapy within 72 hrs after the onset of fever were independent prognostic factors. The mortality was significantly reduced in patients with high-risk factors of IFD if they initiate antifungal treatment within 72 hrs after the onset of fever compared to the patients not. Conclusion: The morbidity and mortality of IFD increase significantly in HM patients with BSI. Early antifungal therapy may improve prognosis in HM patients with BSI complicated with IFD risk factors.
登录
查看更多内容
影响因子:
1.4
作者:
Hirozumi Sano;R. Kobayashi;D. Suzuki;K. Kishimoto;K. Yasuda;K. Kobayashi
通讯作者:
Hirozumi Sano;R. Kobayashi;D. Suzuki;K. Kishimoto;K. Yasuda;K. Kobayashi
影响因子:
5.5
作者:
Criscuolo, Marianna;Marchesi, Francesco;Russo, D.
通讯作者:
Russo, D.
DOI:
10.1111/j.1469-0691.2012.03906.x
发表时间:
2013-01
期刊:
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
影响因子:
--
作者:
Kim SH;Yoon YK;Kim MJ;Sohn JW
通讯作者:
Sohn JW
DOI:
10.1186/cc10574
发表时间:
2011
期刊:
Critical care (London, England)
影响因子:
--
作者:
Muskett H;Shahin J;Eyres G;Harvey S;Rowan K;Harrison D
通讯作者:
Harrison D
DOI:
10.6004/jnccn.2008.0013
发表时间:
2012
期刊:
Journal of the National Comprehensive Cancer Network : JNCCN
影响因子:
--
作者:
L. Baden;W. Bensinger;M. Angarone;C. Casper;E. Dubberke;A. Freifeld;R. Garzon;J. Greene;J. Greer;J. Ito;J. Karp;D. Kaul;E. King;Emily R. Mackler;K. Marr;J. Montoya;Ashley Morris-Engemann;P. Pappas;K. Rolston;B. Segal;S. Seo;S. Swaminathan;M. Naganuma;Dorothy Shead
通讯作者:
L. Baden;W. Bensinger;M. Angarone;C. Casper;E. Dubberke;A. Freifeld;R. Garzon;J. Greene;J. Greer;J. Ito;J. Karp;D. Kaul;E. King;Emily R. Mackler;K. Marr;J. Montoya;Ashley Morris-Engemann;P. Pappas;K. Rolston;B. Segal;S. Seo;S. Swaminathan;M. Naganuma;Dorothy Shead